材料科学
小分子
体内
癌症治疗
过渡金属
癌症
铬
纳米技术
癌症研究
化学
生物化学
生物
冶金
医学
内科学
催化作用
生物技术
作者
Miao Chen,Xiaoting Huang,Hua-Tian Shi,Jie Lai,Li Ma,Tai-Chu Lau,Tianfeng Chen
出处
期刊:Biomaterials
[Elsevier]
日期:2021-09-01
卷期号:276: 120991-120991
被引量:14
标识
DOI:10.1016/j.biomaterials.2021.120991
摘要
The development of metal-based anticancer drugs is of considerable interest and significance in inorganic medicine. In contrast to noble metal-based small molecules, the anticancer property of earth abundant metal-based small molecules is much less explored which are usually essential trace element for the human body. Among earth abundant metals, chromium (Cr) in the +3 valent is an essential trace element for the human body to low down the blood lipids and maintain the blood sugar; on the other hand, Cr(VI) are known to be highly toxic due to their oxidation power. To design stable high-valent Cr small molecules to construct Cr(high-valent)-Cr(III) in-situ transition system to achieve low-toxic and highly efficient anti-cancer therapy is a very desirable approach. Herein we report the Cr(V)–Cr(III) in-situ transition system promotes ROS generation to achieve efficient cancer therapy in vivo and in vitro. To the best of our knowledge, these Cr-based small molecules are the first stable Cr(V) compounds with potent anticancer efficacy, especially towards malignant cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI